Long-Acting Injectables For The Treatment Of Bipolar I Disorder: Relevant Questions From Providers

Join us for this lively discussion with Dr. Joseph Goldberg and Dr. Mauricio Tohen regarding long-acting injectables (LAIs) in the treatment of bipolar I disorder. This moderated session explores perception, preferences, challenges, and treatment goals for both patients and providers. Discussants review provider and patient centric perspectives in selecting therapy, plus potential strategies to assess preferences regarding new preventative treatments such as mode of administration, dosing regimen and treatment-related determinants of adherence. 

Objectives:

• Describe the challenges to long-term treatment and the importance of management options in patients diagnosed with Bipolar I Disorder (BP-I)
• Discuss the pros and cons of LAIs for patients living with BP-I, from the provider and patient perspective
• Understand strategies to aid in shared decision making between providers and patients when considering LAIs

Joseph Goldberg, MD

Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai

More

Joseph F. Goldberg, MD is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai. He attended college at the University of Chicago, graduate school in neuroscience at the University of Illinois, and medical school at Northwestern University. He completed his residency and chief residency in psychiatry, and fellowship in psychopharmacology, at the Payne Whitney Clinic, New York Presbyterian Hospital, where he later served on the faculty and was site Principal Investigator at Weill-Cornell Medical Center for the NIMH STEP-BD program. He has published over 200 peer-reviewed papers on topics related mainly to the treatment and clinical features of bipolar disorder, as well as three books on bipolar disorder and psychopharmacology, most recently “Managing the Side Effects of Psychotropic Medications, 2nd edition” published in 2019 by American Psychiatric Publishing, and the forthcoming “Practical Psychopharmacology” by Cambridge University Press. He serves on the Board of Directors for the American Society of Clinical Psychopharmacology and is on the editorial boards for a number of peer-reviewed journals. His research has been awarded funding from NARSAD, NIMH, the Stanley Foundation, and the American Foundation for Suicide Prevention. Dr. Goldberg is a Distinguished Fellow of the American Psychiatric Association and has been listed for many years in Best Doctors in America and Castle Connolly’s “America’s Top Doctors.”

Mauricio Tohen, MD, DrPH, MBA

Chairman, Department of Psychiatry and Behavioral Sciences, Distinguished University Professor, University of New Mexico

More

Dr. Tohen is a Distinguished University Professor at the University of New Mexico and the Chairman of the University of New Mexico’s Department of Psychiatry and Behavioral Sciences. With more than 350 publications and 20,000 scientific citations to his name, Dr. Tohen received in 2016 the Mogens Schou Award for Education and Teaching from the International Society for Bipolar Disorders. In 2017, Dr. Tohen was recognized as one of the world’s leading experts on bipolar disorder based on the breadth and depth of his publications. He earned his medical degree from the National University of Mexico and his Doctorate in Public Health (Epidemiology) from Harvard University. His postdoctoral training included a residency in Psychiatry at the University of Toronto, where he additionally obtained a DPsych (Diploma) in Psychiatric Research, and a fellowship at McLean Hospital, Harvard Medical School in Psychopharmacology. Dr. Tohen also obtained an MBA degree from the Indiana University Kelly School of Business. 

Michael Aldape, PhD (OPDC)

Senior Medical Science Liaison

Follow-Up Q&A

Joseph Goldberg, MD and Mauricio Tohen, MD, DrPH, MBA are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Michael Aldape, PhD is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)